Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Sulfacetamide + prednisolone is a combination ophthalmic medication containing two active ingredients: sulfacetamide, a sulfa antibiotic, and prednisolone, a corticosteroid. Sulfacetamide inhibits bacterial growth by interfering with folic acid synthesis in susceptible bacteria, providing bacteriostatic action against organisms such as Escherichia coli, Staphylococcus aureus, Streptococcus (viridans group), Haemophilus influenzae, Klebsiella species, and Enterobacter species. Prednisolone acts as an anti-inflammatory agent by suppressing the immune response to reduce swelling, redness, itching, and pain in the eye. This combination is primarily used to treat inflammatory ocular conditions where there is either an existing bacterial infection or risk of one—such as conjunctivitis or chronic anterior uveitis—and for preventing damage from chemicals or foreign objects in the eye. The product is available as an ophthalmic solution or ointment for topical use only[1][2][3][4][5][7].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on sulfacetamide + prednisolone.